Trial Profile
Multicenter Open-label, Phase II Trial, to Evaluate the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Patients With HER2-negative Breast Cancer (The Phenomenal Study)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PHENOMENAL
- Sponsors Medica Scientia Innovation Research
- 28 Feb 2024 Planned End Date changed from 1 Dec 2024 to 31 Mar 2024.
- 27 Jul 2023 Planned End Date changed from 30 Jun 2023 to 1 Dec 2024.
- 27 Jul 2023 Planned primary completion date changed from 30 Apr 2023 to 31 Dec 2023.